Original Research Article
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease DementiaMollenhauer B.a, g · Trenkwalder C.d, e · von Ahsen N.b · Bibl M.c · Steinacker P.a, h · Brechlin P.a · Schindehuette J.d · Poser S.a · Wiltfang J.f · Otto M.a, c, h
Departments of aNeurology, bClinical Chemistry, cPsychiatry and dClinical Neurophysiology, Georg-August University, eParacelsus-Elena Clinic, Kassel, and fDepartment of Psychiatry, Friedrich-Alexander University, Erlangen/Nuremberg, Germany; gCenter for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass., USA; hDepartment of Neurology, University of Ulm, Ulm, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Measurement of τ-protein and β-amyloid1–42 (Aβ42) in cerebrospinal fluid (CSF) has gained increasing acceptance in the differential diagnosis of Alzheimer’s disease. We investigated CSF τ-protein and Aβ42 concentrations in 73 patients with advanced idiopathic Parkinson’s disease with dementia (PDD) and 23 patients with idiopathic Parkinson’s disease without dementia (PD) and in a comparison group of 41 non-demented neurological patients (CG) using commercially available enzyme-linked-immunoabsorbant-assay (ELISA). τ-Protein levels were statistically significantly higher and Aβ42 lower in the PDD patients compared to PD patients and the CG. This observation was most marked (p < 0.05) in a subgroup of patients with PDD carrying the apolipoprotein genotype Ε3/Ε3. The distribution of the apolipoprotein genotypes in PDD and PD patients was similar to that of the CG. Although a significant difference in τ-protein values was observed between PDD and CG, no diagnostic cut-off value was established. These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD.
© 2006 S. Karger AG, Basel
- Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
- Aarsland D, Karlsen K: Neuropsychiatric aspects of Parkinson’s disease. Curr Psychiatry Rep 1999;1:61–68.
- Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P: Risk of dementia in Parkinson’s disease. Neurology 2001;56:730–736.
- Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50:140–148.
- Louis ED, Marder K, Cote L, et al: Mortality from Parkinson’s disease. Arch Neurol 1997;54:260–264.
- Aarsland D, Larsen JP, Karlsen K, et al: Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866–874.
- Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM: Decreased β-amyloid and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094–2103.
- Galasko D: Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer’s disease. J Neural Transm Suppl 1998;53:209–221.
- Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD-patients using β-amyloid (1–42) and tau levels in CSF. Neurology 1999;52:1555–1562.
Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J: Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004;25:263–281.
- Kahle PJ, Jawonek M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, et al: Combined assessment of tau protein and neuronal thread protein in Alzheimer’s disease CSF. Neurology 2000;54:1498–1504.
- Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–245.
- Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al: Both total tau and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:624–630.
Sjögren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanstichele H, et al: CSF levels of tau, beta-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;54:1960–1979.
- Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, Orti-Pareja M, Berbel A, Tallon-Barranco A, et al: Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson’s disease patients. Neurosci Lett 1997;238:139–141.
Jansen SE, Vermes I, de Vos RA: Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson’s disease. Lancet 1998;351:1105–1106.
- Kanemaru K, Kameda N, Yamanouchi H: Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000;54:1875–1876.
- Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP: Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001;304:102–106.
- Holmberg B, Johnels B, Blennow K, Rosengren L: Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Move Disord 2003;18:186–190.
- Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.
- Hoehn MM, Yahr MD: Parkinsonism: onset and mortality. Neurology 1967;17:427–442.
Fahn S, Elton RL, and members of the UPDRS Development Committee: Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Goldstein M, Calne DB (eds): Recent Developments in Parkinson’s Disease. Florham Park, MacMillan Health Care Information, 1987, vol 2, pp 153–163.
- Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
Deutsche Neurologische Gesellschaft (DGN): Parkinsonsyndrome; in Diener HC (ed): Leitlinien für Diagnostik und Therapie in der Neurologie, September 2003. Stuttgart, Thieme, 2003.
- Goetz CG: Treatment of advanced Parkinson’s disease: an evidence-based analysis. Adv Neurol 2003;91:213–228.
- Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mader M, Weber T: S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566–570.
- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ: Mutant presinilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67–72.
- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ: Amyloid precursor protein processing and Aβ42 deposition in transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 1997;94:1550–1555.
- Aurell A, Rosengren LE, Wikkelsö C, Nordberg G, Haglid KG: The S-100 protein in cerebrospinal fluid: a simple ELISA method. J Neurol Sci 1998;89:157–164.
- von Ahsen N, Oellerich M, Armstrong VW, Schütz E: Application of a thermodynamic nearest-neighbor model to estimate nucleic acid stability and optimize probe design: prediction of melting points of different mutations of apolipoprotein B 3500 and factor V Leiden with a hybridization probe genotyping assay on the Lightcycler. Clin Chem 1999;45:2094–2101.
- Youden JW: Index rating for diagnostic tests. Cancer 1950;3:32–35.
- El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D: Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945–1947.
- Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al: Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 2001;47:1776–1781.
- Verbeek MM, De Jong D, Kremer HP: Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003;40:25–40.
- McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosako K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetove-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005, Epub ahead of print.
- Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–2518.
- Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG: A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938–944.
- Brown DF, Dababo MA, Bigio EH, Risser RC, Eagans KP, Hladik CL, White CL: Neuropathologic evidence that the Lewy body variant of Alzheimer’s disease represents coexistence of Alzheimer’s disease and idiopathic Parkinson’s disease. J Neuropathol Exp Neurol 1998;57:39–46.
- Lippa CF, Smith TW, Swearer JM: Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81–88.
- Mattila PM, Roytta M, Torikka H, et al: Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. Acta Neuropathol 1998;95:576–582.
- Hurtig HI, Trojanowski JQ, Galvin J, et al: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000;54:1916–1921.
- Strozyk D, Blennow K, White LR, Launer LJ: CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652–656.
- Pitschke M, Prior R, Haupt M, Riesner D: Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopy. Nat Med 1998;4:832–834.
- Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, et al: Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aβ peptides. Electrophoresis 2004;25:2912–2918.
- Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al: Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and patients with chronic neuroinflammation. J Neurochem 2002;81:481–496.
- Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M: Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003;54:263–267.
- Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J: Decreased beta-amyloid1–42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54:1099–1102.
- Henderson AS, Easteal S, Jorm AF, MacKinnon AJ, Koreten AE, Christensen H, et al: Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387–1390.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al: Protective effect of apolipoprotein E type 2 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
- Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, et al: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
- Mattila PM, Koskela T, Roytta M, Lehtimaki T, Pirttila TA, Ilveskoski E, Karhunen P, Rinne JO: Apolipoprotein E epsilon4 allele frequency is increased in Parkinson’s disease only with co-existing Alzheimer pathology. Acta Neuropathol 1998;96:417–420.
- Blomberg M, Jensen M, Basum H, Lannfeld L, Wahlund LO: Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci Lett 1996:214:163–166.
- Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okimoto K, Shoji M: Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer’s disease. Neurosci Lett 1999:65–68.
- Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K: APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004;62:2116–2118.
- Tapiola T, Pirttila T, Mehta SP, Alafuzoff I, Lehtovira M, Soininen H: Relationship between apoE genotype and CSF beta amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging 2000;21:735–740.
- Jellinger KH, Seppi K, Wenning GK, Poewe W: Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 2002;109:329–339.
- Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T: Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003;60:1218–1222.
- Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Tau protein, beta-amyloid1–42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005;19:164–170.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.